Want to see SE:DPHA full AI Analyst Report?
Guard Therapeutics International AB (DPHA) Ratios
Guard Therapeutics International AB Ratios
SE:DPHA's free cash flow for Q1 2026 was $-8.90M. For the 2026 fiscal year, SE:DPHA's free cash flow was increased by $0.00 and operating cash flow was $-8.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.36 | 3.14 | 5.13 | 8.93 | 17.40 |
| Quick Ratio | 5.36 | 3.14 | 5.13 | 8.93 | 17.40 |
| Cash Ratio | 4.93 | 3.06 | 5.04 | 8.86 | 17.24 |
| Solvency Ratio | -8.06 | -5.40 | -6.13 | -4.39 | -5.60 |
| Operating Cash Flow Ratio | -10.83 | -5.34 | -6.99 | -4.50 | -7.09 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 40.63M | $ 37.97M | $ 66.73M | $ 177.35M | $ 175.75M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.33 | 1.47 | 1.28 | 1.14 | 1.08 |
| Debt Service Coverage Ratio | -48.25 | -12528.63 | -257.06 | -110741.00 | -82143.00 |
| Interest Coverage Ratio | -48.25 | -12488.13 | -257.43 | -114921.00 | -81900.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.12 | 0.00 | 0.04 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.46 | 0.54 | 0.73 | 1.78 | 2.30 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 98.15% | 100.16% |
| EBT Per EBIT | 101.03% | 96.16% | 98.48% | 98.19% | 100.16% |
| Return on Assets (ROA) | -201.04% | -172.34% | -132.97% | -54.67% | -43.14% |
| Return on Equity (ROE) | -267.90% | -253.03% | -169.82% | -62.45% | -46.74% |
| Return on Capital Employed (ROCE) | -244.62% | -262.87% | -167.71% | -63.88% | -45.63% |
| Return on Invested Capital (ROIC) | -244.62% | -262.87% | -167.71% | -62.70% | -45.63% |
| Return on Tangible Assets | -201.04% | -172.34% | -132.97% | -54.67% | -43.14% |
| Earnings Yield | -410.64% | -46.55% | -33.36% | -41.17% | -1.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -133687.33 | -273020.00 | -153032.33 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 133687.33 | 273020.00 | 153032.33 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.06 | -8.50 | -11.53 | -14.49 | -0.70 |
| Free Cash Flow Per Share | -6.06 | -8.50 | -11.53 | -14.49 | -0.70 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -412.52% | -45.91% | -34.16% | -37.97% | -1.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.24 | -2.15 | -3.00 | -2.43 | -84.85 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.65 | 5.44 | 5.09 | 1.52 | 39.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.24 | -2.18 | -2.93 | -2.63 | -89.84 |
| Price-to-Operating Cash Flow Ratio | -0.24 | -2.18 | -2.93 | -2.63 | -89.84 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.09 | 0.11 | -0.00 | -0.46 |
| Enterprise Value Multiple | 0.22 | -1.52 | -2.23 | -0.60 | -82.70 |
| Enterprise Value | -23.32M | 152.20M | 255.94M | 67.99M | 6.78B |
| EV to EBITDA | 0.22 | -1.52 | -2.23 | -0.60 | -82.70 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.21 | -1.61 | -2.21 | -0.67 | -87.41 |
| EV to Operating Cash Flow | 0.21 | -1.61 | -2.21 | -0.67 | -87.41 |
| Tangible Book Value Per Share | 2.25 | 3.41 | 6.63 | 25.17 | 1.59 |
| Shareholders’ Equity Per Share | 2.25 | 3.41 | 6.63 | 25.17 | 1.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.02 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -6.04 | -8.62 | -11.26 | -15.72 | -0.74 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.00 |
| Interest Burden | 1.01 | 0.96 | 0.99 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.00 | 0.95 | 1.02 | 0.89 | 0.95 |
Currency in SEK